TABLE 2.
Crossover Study Participant Baseline Characteristics
| Characteristic | Placebo Then Varenicline, n = 16 | Varenicline Then Placebo, n = 18 |
|---|---|---|
| Age, yr | ||
| Mean (SD) | 64.2 (5.3) | 68.1 (5.7) |
| min, max | 52, 76 | 56, 78 |
| Male, n (%) | 13 (81%) | 15 (83%) |
| White, n (%) | 16 (100%) | 17 (94%) |
| Age at diagnosis, yr | ||
| Mean (SD) | 57.7 (7.22) | 61.3 (6.66) |
| min, max | 43, 70 | 50, 74 |
| MDS-UPDRS III | ||
| Mean (SD) | 30.7 (12.4) | 33.2 (13.92) |
| min, max | 13, 62.5 | 15, 58 |
| GDS | ||
| Mean (SD) | 4.3 (4.19) | 2.4 (2.06) |
| min, max | 0, 15 | 0, 6 |
| MoCA | ||
| Mean (SD) | 26.8 (1.97) | 27.2 (2.37) |
| min, max | 24, 30 | 23, 30 |
MDS-UPDRS III: motor subscale score; range = 0–137, with higher scores indicating worse symptoms. GDS: total score; range = 0–30, with higher scores indicating worse depression. MoCA: total score; range = 0–30, with lower scores indicating worse severity.
GDS = Geriatric Depression Scale; max = maximum; MDS-UPDRS III = Movement Disorder Society Unified Parkinson’s Disease Rating Scale, part III; min = minimum; MoCA = Montreal Cognitive Assessment; SD = standard deviation.